Abivax
ABVX.PAAbivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Drugs in Pipeline
1
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ABX464 | Phase 3 | Human Immunodeficiency Virus Infections | - | - |
Human Immunodeficiency Virus Infections
1 drug in this indication
Inflammatory Bowel Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Abivax's drug pipeline?→
CatalystAlert tracks 1 drug candidate in Abivax's (ABVX.PA) pipeline across Phase 3. Its lead program is ABX464 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Abivax's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Abivax (ABVX.PA) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ABVX.PA biotech catalysts?→
Add ABVX.PA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Abivax's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.